Company started with operations at Bollaram facility
1999
Further expansion of Bollaram facility
2002
WHO-GMP approvals for facilities
2004-05
Started filing DMFs and COSs starting with EU and Canada
Entered into strategic partnership with Acino
2006
US-DMF filed for Amlodipine Besylate
2007
Developed Raloxifene API & filed DMF/CEP
USFDA approval for Bollaram facility
EU-GMP for Amlodipine Besylate
2008-09
All facilities were USFDA and EU - GMP approved
2012
Started FDF facility in Jadcherla SEZ
USFDA approval renewed for Vizag
2013
Divested Jadcherla FDF facility to Mylan
Started a new FDF company "Evertogen" in partnership with Organosyn
2015
Facility was reinspected by USFDA with “zero “ Form 483 observations.
2016
Sold Vizag facility to Torrent along with Raloxifene API & related DMF/CEP
2017
Converted into a Pvt Ltd company
2018
Acquired adjoining land (~6,300 sq mtrs) of the current manufacturing and constructed new warehouse, QC block & intermediate drying area to facilitate expansion, ease of operation and stricter compliances
2019
Re-acquired Raloxifene API along with DMF/CEP from Torrent & signed a CMO agreement with Melody.
The Facility was inspected and approved by TGA and PMDA.
2020
The Facility was inspected (desktop) by USFDA in April/May 20. The inspection is closed / approved
DMF for Amlodipine has been filed in China
Added two new big clients for Amlodipine
2021
New Pharma block added
Expansion of intermediate manufacturing area
Added one more Micronizer to increase productivity and with a view to have a separate dedicated micronization line for each product
Received CFE from TSPCB for expansion of production capacities
2022
New MEE & ZLD added with the capacity of 100 KLD to take care of increasing production capacities
2023
Capacity enhancement of Amlodipine Besilate.
Capacity enhancement of Cetirizine Di-Hydrochloride.
Retro-fitment of Distillation column has been completed.
Added one more Micronizer to meet the customer requirement.